电磁辐射对大鼠内皮祖细胞和肾脏组织学的影响

目的:研究电磁辐射对体外培养骨髓来源的内皮祖细胞(EPCs)增殖、迁移、黏附能力的影响,并探讨其与肾脏疾病的可能关系。方法:密度梯度离心法获取大鼠骨髓单个核细胞(MNCs),接种至纤维连接素包被的培养板上,培养6d后进行免疫细胞化学和免疫荧光鉴定EPCs。采用MTT比色法、Transwell小室和黏附能力测定实验,观察平均功率密度为65mW/cm2,时间20min的电磁辐射对EPCs的增殖、迁移、黏附能力的影响;同等剂量全身照射大鼠,光镜和透射电镜观察大鼠肾脏组织学和超微结构的变化。结果:从大鼠骨髓能成功分离培养获得EPCs。EPCs的增殖、迁移、黏附能力较对照组显著下降;大鼠接受全身照射后各时相点无明显组织学改变,但超微结构显示在照射后3h后开始出现肾小球毛细血管袢足突肿胀,12h后出现部分足突融合。结论:电磁辐射导致EPCs生物功能显著减弱,肾小球超微结构改变,电磁辐射可能与起肾脏疾病的发生有关。     

miR-92a对大鼠骨髓源性内皮祖细胞功能的影响

该文探讨了mi R-92a对大鼠骨髓源性内皮祖细胞(endothelial progenitor cells,EPCs)迁移、黏附、增殖以及血管形成能力等的影响。采用密度梯度离心法分离大鼠骨髓来源的单核细胞,体外培养于含10%胎牛血清的EGM-2MV完全培养基中。利用LipofectamineTM 3000分别将mi R-92a模拟物(mi R-92a mimics)、mi R-92a抑制剂(mi R-92a inhibitor)及其对应的对照组(negative control,NC)转染入第3~5代EPCs,即晚期EPCs。采用改良Boyden小室、黏附实验、CCK-8及Matrigel胶分别检测EPCs迁移、黏附、增殖及体外成血管能力。mi R-92a模拟物明显抑制了EPCs的迁移和体外成血管能力(P0.05),但不影响EPCs的黏附和增殖能力;而mi R-92a抑制剂则促进了EPCs的迁移和体外成血管能力(P0.05),亦不影响EPCs的黏附和增殖能力。结果表明,mi R-92a可抑制EPCs的迁移及体外成血管能力。该研究结果将为临床以mi R-92a和EPCs为靶点防治动脉粥样硬化性心血管疾病提供理论及实验依据。     

载脂蛋白A损伤小鼠骨髓源性EPCs血管发生能力及其机制

改善血流、促进血管新生是缺血性外周血管疾病的重要治疗措施．由于载脂蛋白A(ApoA)与纤溶酶原(plasminogen,Plg)具有75%～98%的结构同源性,因此,ApoA也可能通过类似Plg的方式抑制内皮祖细胞(endothelial progenitor cells,EPCs)增殖、黏附及迁移而影响血管发生的能力．本文研究ApoA对EPCs 血管发生的影响及机制．为了编码人ApoA全长cDNA序列的pSG-5表达载体,转染COS-7细胞株后进行培养,收集培养液,免疫亲和层析法分离纯化ApoA蛋白;从转ApoA基因小鼠、野生型对照鼠及正常对照鼠骨髓分离培养EPCs,经ApoA处理后移植下肢缺血实验小鼠,于移植后第3、7、14天后观察ApoA对EPCs黏附、迁移及血管发生能力的影响．研究发现,ApoA能显著降低 EPCs的黏附、迁移能力,Matrigel胶上,EPCs血管腔样结构严重破坏,体内实验揭示,EPCs归巢至ApoA转基因小鼠缺血组织血管周围的数量及毛细血管数量显著减少．结果表明,ApoA能损伤EPCs的黏附、迁移及归巢,最终损伤EPCs的血管发生能力．     

地骨皮提取液对内皮祖细胞功能的影响

通过观察地骨皮提取液对高糖培养的人脐血内皮祖细胞(EPCs)的黏附、迁移、增殖等能力的影响,探讨地骨皮提取液对高糖所致的血管内皮损伤是否具有保护作用。分离人脐血单个核细胞,接种培养后收集贴壁细胞,采用双荧光染色法及ecNOS和Flk-1基因的表达对EPCs的生物学特征进行鉴定。将分离到的EPCs分成5组:正常对照NG组、高糖HG组、HG+地骨皮提取液不同浓度组(1 g/组、2 g/L组和4 g/L组);用重贴壁法测定EPCs黏附能力,改良Boyden小室法测定其迁移能力及CCK-8法测定增殖能力。结果显示:(1)HG组EPCs的黏附、迁移及增殖能力较NG组明显下降;(2)HG+地骨皮提取液不同浓度组EPCs黏附、迁移和增殖能力均比HG组高;对迁移和增殖能力的影响以2 g/L干预组效果最为明显。提示地骨皮提取液能部分恢复高糖对EPCs黏附、迁移及增殖能力的抑制,对高糖所致的血管内皮损伤具有保护作用。     

抗坏血酸对糖尿病肾脏足细胞的作用及机制探讨

目的：研究抗坏血酸对糖尿病大鼠肾小球滤过屏障最外层足细胞的作用,并探讨其可能的作用机制。方法：采用腹腔注射链脲佐菌素建立糖尿病大鼠模型,经抗坏血酸治疗5周后,测定血糖（BG）、糖化血红蛋白（HbA1c）、24 h尿白蛋白排泄率（UAER）、肾皮质超氧化物歧化酶（SOD）、过氧化氢酶（CAT）和丙二醛（MDA）水平,并观察足细胞超微结构,检测足细胞损伤标志-desmin蛋白的表达。结果：与正常对照组大鼠比较,糖尿病组大鼠血BG、HbA1c显著增高,肾皮质SOD、CAT活性显著降低,MDA含量、肾小球内desmin蛋白表达明显增加,足细胞足突融合显著,UAER显著升高（均P〈0.05）;与糖尿病组大鼠比较,在血BG、HbA1c无明显差异条件下（均P〉0.05）,抗坏血酸可明显增加糖尿病大鼠肾皮质SOD活性,降低肾皮质MDA含量和desmin蛋白表达水平,并显著减轻足细胞足突融合,减少UAER（均P〈0.05）,肾皮质CAT活性虽有一定程度增高但差异无显著性（P〉0.05）。结论：糖尿病大鼠肾小球滤过屏障最外层足细胞有明显损害,补充抗坏血酸对足细胞起保护作用,其机制可能与增强肾脏抗氧化能力,减轻肾脏氧化应激有关。     

血脂康胶囊对高脂模型大鼠EPCs功能的影响

目的:高脂血症可增加心血管事件的发生率,本研究降脂红曲制剂血脂康胶囊对高脂模型大鼠的内皮祖细胞(endothelial progenitor cells,EPCs)生物学功能的影响。方法:给予Wistar大鼠高脂饲料30 d,造成高血脂大鼠模型,灌服血脂康胶囊。密度梯度离心法分别分离正常对照组,高脂模型组和血脂康治疗组大鼠骨髓单核细胞,应用EGM-2MV进行体外培养。以4~6代EPCs为靶细胞。采用Edu标记技术、CCK-8检测法、粘附能力测定试验、改良的Boyden小室、Matrigel法、荧光定量RT-PCR等方法分别检测EPCs增殖、粘附、迁移、体外成血管及单核细胞趋化蛋白-1(monocyte chemoattractant protein-1,MCP-1)等炎性因子的表达。结果:高血脂模型组大鼠EPCs的增殖、粘附、迁移及成血管能力均明显低于对照组,但炎症因子MCP-1表达则高于对照组;与高脂模型组EPCs比较,血脂康可明显促进EPCs的增殖、粘附、迁移及成血管,下调MCP-1的表达。结论:高脂状态下大鼠EPCs的增殖、粘附、迁移及成血管等生物学功能受损,血脂康能调整脂质代谢,改善高脂血症大鼠EPCs功能,从而起到保护血管内皮的功能,减少心血管疾病的发生。     

尼氟酸对晚期内皮祖细胞生物学特性的影响

目的:探讨ClCa通道抑制剂--尼氟酸(Niflumic,NFA)对大鼠骨髓来源的晚期内皮祖细胞(endothelial progenitor cells,EPCs)生物学特性的影响。方法:密度梯度离心法分离大鼠骨髓单核细胞,应用EGM-2完全培养液进行体外培养,以第三代或第四代的晚期EPCs作为靶细胞,应用RT-PCR检测晚期EPCs上是否存在Cl Ca通道标志基因TMEM16A和Cl Ca4的表达。采用CCK-8法、Ed U标记法、划痕实验、Boyden小室实验及Matrigel法分别检测10μmol/L NFA对细胞增殖、迁移及体外血管形成能力的影响;应用荧光定量PCR及流式细胞术检测内皮分化标志v WF和CD31基因及蛋白的表达。结果:晚期EPCs表达ClCa通道标志基因TMEM16A和ClCa4;NFA抑制晚期EPCs的迁移功能(P0.05);但对EPCs的增殖、分化及成血管能力有促进作用。NFA上调了晚期EPCs的CD31和v WF基因和蛋白表达。结论:NFA能促进EPCs的增殖、分化及成血管能力,抑制EPCs的迁移能力。NFA对EPCs生物学特性的这类影响将为心血管疾病治疗药物选择方面提供一定的参考依据。     

匹伐他汀对体外培养人脐静脉血内皮祖细胞数量及功能的影响

目的：通过体外培养人脐静脉血内皮祖细胞（endothelial progenitor cells,EPCs）,观察他汀类新药（匹伐他汀）对EPCs数量及增殖、迁移和粘附功能的影响。方法：采用密度梯度离心法分离培养人脐静脉血单个核细胞,将其接种在包被有人纤维连接蛋白培养板上,培养7 d后,收集贴壁细胞,加入不同浓度匹伐他汀（分别为0.001 μmol/L、0.01 μmol/L、0.1 μmol/L、1.0 μmol/L）培养24 h,用免疫荧光法观察EPCs 吸收FITC-UEA-I 和Dil-acLDL情况对EPCs 进行鉴定,然后分别采用MTT 比色法、改良的Boyden小室、粘附能力测定实验对各实验组测定,来观察匹伐他汀对EPCs 数量及增殖、迁移和粘附功能影响。结果：匹伐他汀组与对照组相比,匹伐他汀显著提高了体外培养EPCs的数量及增殖、迁移与粘附能力（P〈0.05）。匹伐他汀浓度在0.1 μmol/L 时对EPCs影响达到最大。随着药物浓度的继续增大,EPCs的上述功能反呈下降趋势,但1.0 μmol/L 组仍高于对照组。结论：匹伐他汀能增加体外培养EPCs的数量及增殖、迁移和粘附能力,可作为EPCs 培养的一种改良方法,为其更好的应用于临床具有重要的意义。     

Podocin蛋白对肾小球足细胞的影响

目的：探讨肾小球足细胞裂隙膜蛋白podocin对足细胞形态及蛋白尿的影响.方法：32只体重160g～220g的雄性SD大鼠按阿霉素给药剂量随机分成小剂量组（3.0mg/Kg）、肾病剂量组（7.5mg/Kg）、超剂量组（10.0mg/Kg）、正常对照组.于给药第三周末处死大鼠,用氯化苄乙氧铵比浊法检测大鼠24h尿蛋白量,用免疫胶体金电镜检测大鼠肾小球蛋白podocin的表达和足细胞形态.结果：阿霉素组大鼠24h尿蛋白排泄量明显高于正常对照组,尤以肾病组最明显（P＜0.05）;正常对照组大鼠podocin分布在靠近肾小球基底膜（GBM）的足突基底部,主要定位于裂隙隔膜的胞质面,部分金颗粒也可发现于GBM稍远的足突细胞表面.肾病组肾小球足突广泛融合,免疫胶体金颗粒几乎见不到;超剂量组和小剂量组podocin分布在靠近肾小球基底膜（GBM）的足突基底部,免疫胶体金颗粒数明显少于正常对照组,有部分足突退缩.结论：（1）podocin表达减少或消失可能是导致肾小球足突细胞融合的关键因素（2）蛋白尿的发生与肾小球足细胞裂隙膜蛋白podocin的减少或缺失有关.     

匹伐他汀对体外培养人脐静脉血内皮祖细胞数量及功能的影响

目的:通过体外培养人脐静脉血内皮祖细胞(endothelial progenitor cells,EPCs),观察他汀类新药(匹伐他汀)对EPCs数量及增殖、迁移和粘附功能的影响。方法:采用密度梯度离心法分离培养人脐静脉血单个核细胞,将其接种在包被有人纤维连接蛋白培养板上,培养7 d后,收集贴壁细胞,加入不同浓度匹伐他汀(分别为0.001μmol/L、0.01μmol/L、0.1μmol/L、1.0μmol/L)培养24h,用免疫荧光法观察EPCs吸收FITC-UEA-I和Dil-acLDL情况对EPCs进行鉴定,然后分别采用MTT比色法、改良的Boyden小室、粘附能力测定实验对各实验组测定,来观察匹伐他汀对EPCs数量及增殖、迁移和粘附功能影响。结果:匹伐他汀组与对照组相比,匹伐他汀显著提高了体外培养EPCs的数量及增殖、迁移与粘附能力(P0.05)。匹伐他汀浓度在0.1μmol/L时对EPCs影响达到最大。随着药物浓度的继续增大,EPCs的上述功能反呈下降趋势,但1.0μmol/L组仍高于对照组。结论:匹伐他汀能增加体外培养EPCs的数量及增殖、迁移和粘附能力,可作为EPCs培养的一种改良方法,为其更好的应用于临床具有重要的意义。     

他汀类药物对外周血内皮祖细胞的影响

本文旨在探讨他汀类药物氟伐他汀对外周血内皮祖细胞(endothelial progenitor cells,EPCs)数量和功能的影响.用密度梯度离心从外周血获取单个核细胞,将其接种在人纤维连接蛋白(human fibronectin)包被的培养板中,培养7 d后,收集贴壁细胞,加入不同浓度氟伐他汀(分别为0.01、0.1、1、10μmol/L)和辛伐他汀(1 μmol/L),培养一定的时间(6、12、24、48 h).用激光共聚焦显微镜鉴定FITC-UEA-I和DiI-acLDL双染色阳性细胞为正在分化的EPCs,用流式细胞仪检测其表面标志进一步鉴定EPCs,在倒置荧光显微镜下计数.采用MTT比色法、改良的Boyden小室、粘附能力测定实验和体外血管生成试剂盒观察EPCs的增殖能力、迁移能力、粘附能力和体外血管生成能力.结果显示,氟伐他汀可显著增加外周血EPCs的数量,并且EPCs数量随氟伐他汀浓度增加及作用时间延长而增加,1 μmol/L浓度氟伐他汀作用24h对EPCs的数量影响最为显著(较对照组增加15倍,P＜0.05).在动物实验中,喂养氟伐他汀3周后,大鼠的EPCs也较对照组增加2倍(P＜0.05),进一步支持了体外实验的结果.氟伐他汀和辛伐他汀也显著改善外周血EPCs的粘附能力、迁移能力、增殖能力和体外血管生成的能力,相同浓度的氟伐他汀和辛伐他汀(1 μmol/L)对EPCs数量和功能的影响并无显著差异.上述观察结果提示他汀类药物可增加EPCs的数量,改善EPCs功能.     

The characteristics of endothelial progenitor cells derived from mononuclear cells of rat bone marrow in different culture conditions

Endothelial progenitor cells (EPCs) derived from bone marrow are known to be heterogeneous. In this study, we tried to find favorable conditions that induce the differentiation of mononuclear cells (MNCs) from bone marrow into EPCs. The differentiation capacity of MNCs from rat bone marrow was investigated in different conditions, such as different media, different induction times and different culture surfaces. The cell morphology and endothelial biomarkers associated with differentiated MNCs were studied. Our results indicated that MNCs cultured in EGM-2MV (Endothelial cell basal medium-2, plus SingleQuots of growth supplements) developed a bursiform shape, a late EPC-like morphology, while MNCs cultured in complete medium (CM, M199 with 10% FBS, 20 ng/mL VEGF and 10 ng/mL bFGF) showed a spindle shape, an early EPC-like morphology. Cells of both morphologies were able to incorporate DiI-ac-LDL and bind lectin in vitro. MNCs cultured in EGM-2MV exhibited a higher proliferation rate and higher eNOS expression than MNCs cultured in CM. MNCs cultured in EGM-2MV had the ability to form tubes on Matrigel. Flow cytometry results indicated that CD133 expression was highest at day 12 and that the greatest number of cells positive for both FLK-1 and CD133 appeared at day 20 from cells cultured in dishes without fibronectin coating. In addition, the expression levels of CD133, CD31 and FLK-1/CD133 were not significantly different between cells of different shapes. Our experiments suggest that MNCs from bone marrow can be differentiated into late EP-like cells in EGM-2MV, which have the ability to rapidly proliferate. These MNCs can also be differentiated into early EP-like cells in CM. Additionally, fibronectin may not be necessary for the differentiation of EPCs to mature ECs after three generations. Differentiated MNCs from bone marrow in EGM-2MV have the characteristics of EPCs, although the expression levels of EPC markers were lower than previously reported.     

CREB-binding protein silencing inhibits thrombin-induced endothelial progenitor cells angiogenesis

Endothelial progenitor cells (EPCs) are known to promote neovascularization in ischemic diseases. Recent evidence from our group suggested that CREB-binding protein (CBP) plays an important role in thrombin-induced EPCs migration. However, whether CBP could regulate EPCs angiogenic properties is unknown. In the present study, we investigated whether CBP silencing could inhibit thrombin-induced EPCs angiogenesis. EPCs isolated from the bone marrow of Sprague–Dawley rats were cultured and identified, and then were treated by thrombin alone or combined with CBP-shRNA lentivirus. The effect of CBP silencing on EPCs proliferation was assessed using BrdU incorporation assay. Cell adhesion and tube formation were detected to evaluate the angiogenic functions. Finally, mRNA and protein expression of relevant angiogenic genes were examined by real-time PCR, western-blot, and enzyme-linked immunoassay respectively. Luciferase reporter gene assay was performed to evaluate NF-κB activity. Administration of thrombin significantly promoted EPCs proliferation and adhesion. Thrombin also increased the tube formation in Matrigel assay. However, these effects of thrombin were abolished by CBP gene silencing. CBP silencing also abrogated thrombin-induced increases of integrin β2 expression. In thrombin-induced EPCs, CBP silencing significantly decreased the secretion of VEGF, IL-6 and suppressed NF-κB activity. In conclusion, thrombin-induced EPCs proliferation, adhesion, and tube formation were inhibited by CBP silencing, indicating that CBP plays an important role in thrombin-induced EPCs neovascularization.     

Transplantation of endothelial progenitor cells for therapeutic neovascularization

Endothelial progenitor cells (EPCs), which were first identified in adult peripheral blood mononuclear cells (MNCs), play an important role in postnatal neovascularization. Tissue ischemia augments mobilization of EPCs from bone marrow into the circulation and enhances incorporation of EPCs at sites of neovascularization. Two methods to obtain EPCs from bone marrow, peripheral blood or cord blood MNCs have been evaluated for therapeutic neovascularization: (1) fresh isolation using anti-CD34, anti-KDR or anti-AC133 antibody, and (2) ex vivo expansion of total MNCs. In an immunodeficient mouse model of hindlimb ischemia, systemic transplantation of human ex vivo expanded EPCs improves limb survival through the enhancement of blood flow in the ischemic tissue. A similar strategy also leads to histological and functional preservation of ischemic myocardium of nude rats. Recently, a preclinical study of catheter-based, intramyocardial transplantation ofautologous EPCs in a swine model of chronic myocardial ischemia demonstrated the therapeutic potential of cell-based therapy, with attenuation of myocardial ischemia and improvement in left ventricular function. These favorable outcomes strongly suggest a therapeutic impact of EPC transplantation in clinical settings. Further basic research, with improved understanding of the mechanisms governing homing and incorporation of EPCs, will be still necessary to optimize the methodology of the cell therapy.     

剪切应力环境下的内皮祖细胞对肝星状细胞增殖和生物功能的影响

目的：研究流体剪切应力条件下的内皮祖细胞（EPCs）对肝星状细胞（HSCs）增殖、粘附、迁移、凋亡等生物学功能以及成纤维化因子α-平滑肌肌动蛋白（α-SMA）、胶原I （Col-I）、胶原III （Col-III）表达的影响。方法：将HSCs与EPCs分别接种于共培养小室的上层和下层,共培养24 h后,给EPCs细胞施加12 dyne/cm²剪切应力,持续24 h。消化细胞,采用CCK-8法检测HSCs的增殖;流式细胞术检测HSCs的凋亡率;细胞贴壁法检测HSCs的粘附功能;Boyden小室检测HSCs的迁移;荧光定量PCR法及Western blot分别检测HSCs的α-SMA、Col-I、Col-III mRNA和蛋白质的表达情况。结果：在剪切应力条件下,EPCs生态小境能明显抑制HSCs的增殖、粘附和迁移能力,促进HSCs凋亡,下调HSCs中Col-I、Col-III mRNA和蛋白质的表达。结论：在剪切应力条件下,EPCs生态小境对HSCs纤维化的发展具有一定抑制作用。     

RGD-peptide presents anti-adhesive effect, but not direct pro-apoptotic effect on endothelial progenitor cells

Circulating endothelial progenitor cells (EPCs) contribute to neovascularization in tumor or ischemic tissues by multi-step events, including adhesion, migration, chemoattraction, and differentiation to endothelial cells. Anti-angiogenic RGD-peptides have been shown to directly induce apoptosis in human umbilical vein endothelial cells (HUVECs) and T cells. Here, we examined the effects of RGD-peptides on EPCs in terms of adhesive differentiation and apoptosis. When mononuclear cells (MNCs) isolated from human cord blood were cultured on fibronectin-coated plates for 7 days, RGD-peptide treatment decreased dose-dependently the number of adherent cells double positive for DiI-ac-LDL uptake and UEA-1 binding. The cells treated with RGD peptide were also stained less strongly by vWF or KDR antibody by immunofluorescence staining. Immobilization of the RGD-peptide promoted cell adhesion, but resulted in a deficiency in the development of ability of ac-LDL uptake and UEA-1 binding, showing an antagonistic effect. Accordingly, ex vivo-cultivated EPCs expressed integrin alpha5, alphav, beta1, beta3, and beta5, and antibodies to integrins alpha5, alphav, and beta1 decreased the number of adherent cells. However, viability of total MNCs containing early EPCs was not affected by RGD-peptide. In addition, neither an increase in apoptotic cell death nor a direct activation of caspase-3 by RGD-peptide was detected in ex vivo-cultivated EPCs, unlike in HUVECs. Interestingly, RGD-peptide rather enhanced Bcl-2 expression in ex vivo-cultivated EPCs and the EPCs themselves with a high Bcl-2/Bax ratio are comparatively resistant to apoptosis. Therefore, these results suggest that RGD-peptides may inhibit EPC differentiation by anti-adhesive effect, but not by a direct pro-apoptotic effect.     

Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood

The aim of this investigation is to determine whether rapamycin treatment has any effect on endothelial progenitor cells (EPCs). Total mononuclear cells (MNCs) were isolated from peripheral blood by Ficoll density gradient centrifugation, and then the cells were plated on fibronectin-coated culture dishes. After 7 days in culture, attached cells were stimulated with rapamycin (in a series of final concentrations: 0.1, 1.0, 2.0 and 5.0 g/ml) for 6, 12, 24 and 48 h. EPCs were characterized as adherent cells, double positive for DiLDL uptake and lectin binding by direct fluorescence staining. EPC proliferation and migration were determined using the MTT assay and a modified version of the Boyden chamber assay, respectively. An EPC adhesion assay was performed by replating the cells on fibronectin-coated dishes; adherent cells were then counted. Tube formation activity was assayed by using a tube formation assay kit and endothelial nitric oxide synthase (eNOS) was assayed by Western blot analysis. Incubation of isolated human MNCs with rapamycin decreased the number of EPCs present; rapamycin also decreased EPCs proliferative, migratory, adhesive, tube formation capacity and eNOS production in a concentration- and time-dependent manner. Rapamycin was found to decrease the number, proliferative, migratory, adhesive and tube formation capacities of the EPCs, and also was found to decreases eNOS in the EPCs.